RE: Lebermetastasen
Ihre Frage ist zu bejahen. Allerdings darf man hierbei nicht zuviel erwarten. Ansprechen von 10-20 %. Und ganz ohne Nebenwirkungen ist das Herceptin auch nicht. Lesen Sie selbst (aus Medline).
First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.
AU: Vogel,-C; Cobleigh,-M-A; Tripathy,-D; Gutheil,-J-C; Harris,-L-N; Fehrenbacher,-L; Slamon,-D-J; Murphy,-M; Novotny,-W-F; Burchmore,-M; Shak,-S; Stewart,-S-J
AD: University of Miami School of Medicine, Miami, FL, USA.
[email protected]
SO: Eur-J-Cancer. 2001 Jan; 37 Suppl 1S25-9
AB: Following confirmation of the appropriate dosage, safety and potential efficacy of Hercep-tin(trastuzumab) in small-scale phase I and II trials involving patients with refractory disease, a large trial was conducted in 222 patients with breast cancer who had relapsed after one or two chemotherapy regimens for their metastatic disease. The results showed a positive and durable overall response rate (15% according to a response evaluation committee (REC) assessment) using trastuzumab monotherapy (initial dose 4 mg/kg intravenously (i.v.) followed by 2 mg/kg i.v. weekly). In another recently completed phase II trial, 113 patients were randomised to two dose levels (initial dose of 4 mg/kg i.v. dose followed by 2 mg/kg i.v. weekly, or initial dose of 8 mg/kg followed by 4 mg/kg i.v. weekly) of single-agent trastuzumab as first-line therapy for metastatic disease. The preliminary overall response rate was 23% based on investigator assessment, and tolerability was excellent as in previous trials; efficacy was similar in both dose groups, but the side-effects tended to be more frequent in the higher dose group. The preferred dosage is the-refore the same as that currently recommended, i.e. an initial dose of 4 mg/kg i.v. followed by 2 mg/kg weekly i.v. until disease progression.
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
AU: Cobleigh,-M-A; Vogel,-C-L; Tripathy,-D; Robert,-N-J; Scholl,-S; Fehrenbacher,-L; Wolter,-J-M; Paton,-V; Shak,-S; Lieberman,-G; Slamon,-D-J
AD: Rush-Presbyterian-St Luke's Medical Center, Chicago, IL 60612, USA.
SO: J-Clin-Oncol. 1999 Sep; 17(9): 2639-48
AB: PURPOSE: Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety of recom-binant humanized anti-HER2 monoclonal antibody as a single agent was evaluated in women with HER2-overexpressing metastatic breast cancer that had progressed after chemotherapy for metastatic disease. PATIENTS AND METHODS: Two hundred twenty-two women, with HER2-overexpressing metastatic breast cancer that had progressed after one or two chemotherapy regimens, were enrolled. Patients received a loading dose of 4 mg/kg intravenously, followed by a 2-mg/kg maintenance dose at weekly intervals. RESULTS: Study patients had advanced me-tastatic disease and had received extensive prior therapy. A blinded, independent response evaluation committee identified eight complete and 26 partial responses, for an objective re-sponse rate of 15% in the intent-to-treat population (95% confidence interval, 11% to 21%). The median duration of response was 9.1 months; the median duration of survival was 13 months. The most common adverse events, which occurred in approximately 40% of patients, were infu-sion-associated fever and/or chills that usually occurred only during the first infusion, and were of mild to moderate severity. These symptoms were treated successfully with acetaminophen and/or diphenhydramine. The most clinically significant adverse event was cardiac dysfunction, which occurred in 4.7% of patients. Only 1% of patients discontinued the study because of treatment-related adverse events. CONCLUSION: Recombinant humanized anti-HER2 monoclonal antibody, administered as a single agent, produces durable objective responses and is well tolerated by women with HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Side effects that are commonly observed with chemotherapy, such as alopecia, mucositis, and neutropenia, are rarely seen.
